The growth hormone ‘Ngenla’ can now be prescribed in general hospitals in Korea.

According to industry sources, Pfizer Korea’s once-weekly growth hormone Ngenla (somatrogon) has passed the drug committee (DC) reviews of tertiary hospitals including Seoul Asan Medical Center and Sinchon Severance Hospital, as well as medical institutions including Kangdong Sacred Heart Hospital, Seoul National University Bundang Hospital, Bundang CHA Hospital, and Ajou University Hospital.

Ngenla, which was listed for reimbursement since September last year, is reimbursed for pediatric patients who meet all of the following conditions: height falls below the 3rd percentile for their chronologic